How much does Necitumumab cost?

Necitumumab is approved along with gemcitabine hydrochloride and cisplatin to treat squamous non-small cell lung cancer that has metastasized (spread to other parts of the body). It is used as first-line treatment. Nexituzumab is also being studied to treat other types of cancer. Nexituzumab is an anti-EGFR recombinant human monoclonal antibody of the IgG1 isotype, which specifically binds to the ligand binding site of human EGFR.

Nexituzumab is a sterile, preservative-free, clear to slightly opalescent, colorless to slightly yellow solution. After dilution, Nexituzumab is available in single-dose vials for intravenous infusion, with each 50 ml (16 mg/ml) bottle containing 800 mg of Nexituzumab. In clinical studies compared with gemcitabine and cisplatin alone, the combination of gemcitabine and cisplatin can significantly prolong the median overall survival (11.5 months vs. 9.9 months) and progression-free survival (5.7 months vs. 5.5 months) in patients with newly treated metastatic squamous non-small cell lung cancer. There was no difference in overall survival, progression-free survival, or overall response rate between patients with non-squamous non-small cell lung cancer treated with nexituzumab plus pemetrexed and cisplatin compared with patients treated with pemetrexed and cisplatin alone.

The generic drug of Nexituzumab has not yet been approved for marketing in China, and therefore it has not been included in medical insurance. The German version of the generic version of Nexituzumab available overseas800mg/50ml may cost more than RMB 10,000 per box (the price may fluctuate due to the exchange rate), which is relatively expensive. Currently, there is no generic version of Nexituzumab on the market. For more drug information and specific prices, please consult Yaode Medical Consultant.